H.C. Wainwright lowered the firm’s price target on Co-Diagnostics (CODX) to $1 from $1.50 and keeps a Neutral rating on the shares following the Q4 report. The firm cites the company’s higher number of shares outstanding and lower cash position for the target cut.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CODX:
- Co-Diagnostics Reports 2024 Financial Results and Strategic Progress
- Options Volatility and Implied Earnings Moves Today, March 27, 2025
- CODX Earnings this Week: How Will it Perform?
- Options Volatility and Implied Earnings Moves This Week, March 24 – March 27, 2025
- Co-Diagnostics wins dismissal of class action lawsuit